Trial · NCT00988429
Adverse events306
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 306
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | Placebo (Safety Population) | 19 | 224 | |
| other | Dizziness | Nervous system disorders | ESL 800 mg QD (Safety Population) | 34 | 216 | |
| other | Dizziness | Nervous system disorders | ESL 1200 mg QD (Safety Population) | 55 | 210 | |
| other | Somnolence | Nervous system disorders | Placebo (Safety Population) | 12 | 224 | |
| other | Somnolence | Nervous system disorders | ESL 800 mg QD (Safety Population) | 16 | 216 | |
| other | Somnolence | Nervous system disorders | ESL 1200 mg QD (Safety Population) | 36 | 210 | |
| other | Nausea | Gastrointestinal disorders | Placebo (Safety Population) | 11 | 224 | |
| other | Nausea | Gastrointestinal disorders | ESL 800 mg QD (Safety Population) | 16 | 216 | |
| other | Nausea | Gastrointestinal disorders | ESL 1200 mg QD (Safety Population) | 32 | 210 | |
| other | Headache | Nervous system disorders | Placebo (Safety Population) | 17 | 224 | |
| other | Headache | Nervous system disorders | ESL 800 mg QD (Safety Population) | 20 | 216 | |
| other | Headache | Nervous system disorders | ESL 1200 mg QD (Safety Population) | 24 | 210 | |
| other | Vomiting | Gastrointestinal disorders | Placebo (Safety Population) | 3 | 224 | |
| other | Vomiting | Gastrointestinal disorders | ESL 800 mg QD (Safety Population) | 6 | 216 | |
| other | Vomiting | Gastrointestinal disorders | ESL 1200 mg QD (Safety Population) | 23 | 210 | |
| other | Diplopia | Eye disorders | Placebo (Safety Population) | 4 | 224 | |
| other | Diplopia | Eye disorders | ESL 800 mg QD (Safety Population) | 14 | 216 | |
| other | Diplopia | Eye disorders | ESL 1200 mg QD (Safety Population) | 22 | 210 | |
| other | Vertigo | Ear and labyrinth disorders | Placebo (Safety Population) | 1 | 224 | |
| other | Vertigo | Ear and labyrinth disorders | ESL 800 mg QD (Safety Population) | 6 | 216 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00988429/events